RIVAROXABAN (Xarelto®)

Clinical Indication

Preventing atherothrombotic events in people with coronary or peripheral artery disease

Comments

In line with NICE TA607

Date of classification

January 2020

Review date

January 2020

Amber SIMPLE

Drugs suitable to be initiated and prescribed in primary care only after specialist assessment and recommendation. A shared care agreement is not required.